Jun 27 |
Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy
|
Jun 27 |
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
|
Jun 27 |
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
|
Jun 26 |
Verona wins FDA approval of ensifentrine for COPD; stock surges 20%
|
Jun 26 |
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
|
Jun 24 |
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
|
Jun 20 |
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
|
Jun 13 |
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
May 29 |
Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024
|
May 23 |
Verona Pharma: Key Inflection Point Directly Ahead
|